Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation
- PMID: 14696397
Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation
Abstract
Background/aims: TIPS (transjugular intrahepatic portosystemic stent-shunt) has been used increasingly in the management of refractory variceal bleeding. Its role in the management of refractory ascites and hepatorenal syndrome still awaits further prospective studies. Type-2 hepatorenal syndrome is a moderate steady renal impairment. It arises spontaneously and it is the main mechanism of refractory ascites. Precipitating factors may lead to type-1 hepatorenal syndrome. Hepatorenal syndrome is a common complication of advanced cirrhosis with a 3-month mortality of more than 90% unless treated by orthotopic liver transplantation. However, because of the short survival of patients with hepatorenal syndrome and the limited availability of organs, only a small percentage of patients with hepatorenal syndrome can actually reach orthotopic liver transplantation. That is why awaiting orthotopic liver transplantation we have submitted some suitable patients to a TIPS setting.
Methodology: We have considered eighteen consecutive patients affected by advanced cirrhosis (Child-Pugh 10-12) awaiting orthotopic liver transplantation and suitable for TIPS treatment for the presence of type-2 hepatorenal syndrome (10 males, average age 44.5). The criteria for the diagnosis of hepatorenal syndrome and refractory ascites have been effected according to a consensus recommendation. Organic kidney disease was excluded. After mild intravenous sedation and analgesia a puncture needle was advanced transjugular in a catheter through the inferior cava into one of the three hepatic veins. Subsequently, an intrahepatic branch of the portal vein was punctured and the shunt was established by the implantation of Wallstent (diameter 10 mm; Boston, Scientific, Natick, MA). In all patients, we compared serum creatinine, creatinine-clearance, sodium excretion and urine volume before the intervention and 12 weeks after TIPS. The differences among groups were analyzed using paired Student's t-test.
Results: The stent shunt was successfully established in all eighteen patients. Complications occurred in 4 patients (temperature above 38 degrees C or vomiting). No patients have developed hepatic encephalopathy resistant to medical treatment. As for the ascites a complete response with total remission of ascites was obtained in eight patients, while a partial response with the presence of sonographically detectable ascites--without the need of paracentesis--was obtained in ten patients. As regards renal functional parameters we have evidenced a significant improvement after TIPS.
Conclusions: We can notice how the setting of TIPS, at least in the presented case, has allowed the treatment of ascites and, furthermore, has lead to improvement of the renal functional parameters. It all implies the enormous advantage of a better management of the patient waiting for orthotopic liver transplantation and, most of all, the advantage of preparing the patient for the surgical intervention with normal renal functional parameters: in fact, it is well known that the increase of serum creatinine influences the pre- and post-orthotopic liver transplantation course, and in particular can modify the mortality rate of the patient list. The lack of effective alternative treatment modalities and the almost universally fatal outcome of hepatorenal syndrome make TIPS an attractive option in the treatment of hepatorenal syndrome as a bridge to orthotopic liver transplantation.
Similar articles
-
The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites.N Engl J Med. 1995 May 4;332(18):1192-7. doi: 10.1056/NEJM199505043321803. N Engl J Med. 1995. PMID: 7700312
-
Predictors of clinical response to transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients with refractory ascites.Am J Gastroenterol. 1999 May;94(5):1361-5. doi: 10.1111/j.1572-0241.1999.01112.x. Am J Gastroenterol. 1999. PMID: 10235219
-
Transjugular intrahepatic portosystemic shunt in the management of ascites and hepatorenal syndrome.Eur J Gastroenterol Hepatol. 2006 Nov;18(11):1143-50. doi: 10.1097/01.meg.0000236872.85903.3f. Eur J Gastroenterol Hepatol. 2006. PMID: 17033432 Review.
-
Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis.Gastroenterology. 2002 Dec;123(6):1839-47. doi: 10.1053/gast.2002.37073. Gastroenterology. 2002. PMID: 12454841 Clinical Trial.
-
The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension.J Clin Gastroenterol. 2007 Nov-Dec;41 Suppl 3:S344-51. doi: 10.1097/MCG.0b013e318157e500. J Clin Gastroenterol. 2007. PMID: 17975487 Review.
Cited by
-
Indian College of Radiology and Imaging Evidence-Based Guidelines for Interventions in Portal Hypertension and Its Complications.Indian J Radiol Imaging. 2022 Jan 10;31(4):917-932. doi: 10.1055/s-0041-1740235. eCollection 2021 Oct. Indian J Radiol Imaging. 2022. PMID: 35136505 Free PMC article. Review.
-
Prevention of Cirrhosis Complications: Looking for Potential Disease Modifying Agents.J Clin Med. 2021 Oct 5;10(19):4590. doi: 10.3390/jcm10194590. J Clin Med. 2021. PMID: 34640608 Free PMC article. Review.
-
Renal-function change after transjugular intra-hepatic portosystemic shunt placement and its relationship with survival: a single-center experience.Gastroenterol Rep (Oxf). 2020 Dec 3;9(4):306-312. doi: 10.1093/gastro/goaa081. eCollection 2021 Aug. Gastroenterol Rep (Oxf). 2020. PMID: 34567562 Free PMC article.
-
Recent advances in the understanding and management of hepatorenal syndrome.Fac Rev. 2021 May 21;10:48. doi: 10.12703/r/10-48. eCollection 2021. Fac Rev. 2021. PMID: 34131658 Free PMC article. Review.
-
Nonalcoholic Fatty Liver Disease and Diabetes Mellitus Are Associated With Post-Transjugular Intrahepatic Portosystemic Shunt Renal Dysfunction: An Advancing Liver Therapeutic Approaches Group Study.Liver Transpl. 2021 Feb;27(3):329-340. doi: 10.1002/lt.25949. Epub 2021 Jan 2. Liver Transpl. 2021. PMID: 33217178 Free PMC article.
MeSH terms
LinkOut - more resources
Other Literature Sources
Medical
Research Materials